Trials / Completed
CompletedNCT03047616
A Pilot Study to Develop Predictive Biomarkers for the Response to Immunotherapy in Lung Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 88 (actual)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Several immune checkpoint inhibitors targeting the PD-1 pathway have been developed with clinical trials showing an approximately 20% durable response in unselected patients with advanced non-small cell lung cancer (NSCLC). At the moment, no clear biomarker exists to accurately predict anti-PD1/PDL1 tumor responsiveness. The goal of this study is to broadly discover and evaluate the utility of blood based biomarkers for use in measuring and predicting response to immunotherapy in patients with lung cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Blood and Urine Collection |
Timeline
- Start date
- 2016-11-22
- Primary completion
- 2019-01-01
- Completion
- 2019-05-31
- First posted
- 2017-02-09
- Last updated
- 2021-04-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT03047616. Inclusion in this directory is not an endorsement.